<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03590587</url>
  </required_header>
  <id_info>
    <org_study_id>skmc</org_study_id>
    <nct_id>NCT03590587</nct_id>
  </id_info>
  <brief_title>Rapid Structural and Functional Improvements in Following 0.19 mg Fluocinolone Acetonide (FAc) Implant in Diabetic Macular Edema Patients With Poor Visual Acuity: 12-month Audit Results From United Arab Emirates</brief_title>
  <official_title>Rapid Structural and Functional Improvements in Following 0.19 mg Fluocinolone Acetonide (FAc) Implant in Diabetic Macular Edema Patients With Poor Visual Acuity: 12-month Audit Results From United Arab Emirates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benha University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sheikh Khalifa Medical City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Benha University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Health Authority - Abu Dhabi (HAAD) approved the reimbursement of the slow release FAc
      implant (ILUVIEN) and it is now available for the treatment of diabetic macular edema (DME)
      in persons who have been previously treated with a course of corticosteroids and did not have
      a clinically significant rise in intraocular pressure. We performed a retrospective 12-month
      audit to assess the efficacy and safety of the FAc implant in our clinical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty patients with pseudophakic lenses, treated with ILUVIEN, were investigated to evaluate
      functional and anatomical characteristics and outcomes (visual acuity [VA; ETDRS letters
      score], central macular thickness [CMT] and intraocular pressure [IOP]) at baseline, weeks
      2-4 and months 3, 6 and 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 13, 2017</start_date>
  <completion_date type="Anticipated">September 16, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>BCVA</measure>
    <time_frame>12 months</time_frame>
    <description>best corrected visual acuity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CMT</measure>
    <time_frame>12 months</time_frame>
    <description>Central Macular thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IOP</measure>
    <time_frame>12 months</time_frame>
    <description>Intraocular pressure</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>patients treated with 0.19 mg fluocinolone acetonide (FAc) implant for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.19 mg fluocinolone acetonide (FAc) implant</intervention_name>
    <description>0.19 mg fluocinolone acetonide (FAc) implant</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>0.19 mg fluocinolone acetonide (FAc) implant</intervention_name>
    <description>0.19 mg fluocinolone acetonide (FAc) implant</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Twenty patients with pseudophakic lenses, treated with ILUVIEN, were investigated to
        evaluate functional and anatomical characteristics and outcomes (visual acuity [VA; ETDRS
        letters score], central macular thickness [CMT] and intraocular pressure [IOP]) at
        baseline, weeks 2-4 and months 3, 6 and 12 months.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DME

          -  Pseudophakic

        Exclusion Criteria:

          -  Other causes of macular edema.

          -  Phakic

          -  Know case of gaucoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed Elbarky, MD</last_name>
    <phone>00971557443731</phone>
    <phone_ext>00971557443731</phone_ext>
    <email>AHMED.ALBARQY@fmed.bu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elbarky, MD</last_name>
    <phone>00971557443731</phone>
    <phone_ext>00971557443731</phone_ext>
    <email>AHMED.ALBARQY@fmed.bu.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shiekh Khalifa medical city</name>
      <address>
        <city>Abu Dhabi</city>
        <zip>51900</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Elbarky</last_name>
      <phone>00971557443731</phone>
      <phone_ext>00971557443731</phone_ext>
      <email>AHMED.ALBARQY@fmed.bu.edu.eg</email>
    </contact>
    <investigator>
      <last_name>tarek elhamaky, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Arab Emirates</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 7, 2018</study_first_submitted>
  <study_first_submitted_qc>July 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2018</study_first_posted>
  <last_update_submitted>July 7, 2018</last_update_submitted>
  <last_update_submitted_qc>July 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>Ahmed Elbarky</investigator_full_name>
    <investigator_title>assistant professor of ophthalmologyu</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluocinolone Acetonide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

